- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01087398
Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis
May 31, 2012 updated by: Tehran University of Medical Sciences
The purpose of this study is to evaluate the efficacy and side effects of donor hematopoietic cells using chemotherapy regimen without total-body irradiation in children undergoing a hematopoietic stem cell transplant for Malignant infantile osteopetrosis.
The blood stem cells will be derived from either related donor or unrelated umbilical cord blood or haploidentical donor.
Study Overview
Status
Unknown
Conditions
Study Type
Interventional
Enrollment (Anticipated)
10
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tehran, Iran, Islamic Republic of, 14114
- Recruiting
- Hematology-Oncology & SCT Research Center
-
Sub-Investigator:
- Mahdi Jalili, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 5 years (CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of Osteopetrosis confirm by bone biopsy and radiographic imaging
- Age up to 5 year old
Exclusion Criteria:
- Carbonic Anhydrase II (CAII) deficiency osteopetrosis variant
- Creatinine clearance ≤ 40ml/min/1.73m^2 or RTA
- Bilirubin ≥ 3mg/dL
- SGPT ≥ 500 U/L
- Current severe infection
- Evidence of CNS involvement
- Morbidity such as blindness or deafness
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Intervention
|
For sibling full match:
For other related full match, sibling or other related with one antigen mismatch and umbilical cord blood:
For haploidentical:
Other Names:
Patients undergoing Hematopoietic Stem Cell Transplantation from one of below source:
Other Names:
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall Survival and Progressive Free Survival in patient with infantile Osteopetrosis who receive allogeneic HSCT
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
One year overall survival after allogeneic HSCT
Time Frame: 1 year
|
1 year
|
One year Progressive Free Survival after allogeneic HSCT
Time Frame: 1 year
|
1 year
|
Transplantation Related Mortality (TRM) after allogeneic HSCT
Time Frame: 1 year
|
1 year
|
Acute and chronic GVHD rate after allogeneic HSCT
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2009
Primary Completion (ANTICIPATED)
November 1, 2012
Study Completion (ANTICIPATED)
December 1, 2012
Study Registration Dates
First Submitted
March 13, 2010
First Submitted That Met QC Criteria
March 15, 2010
First Posted (ESTIMATE)
March 16, 2010
Study Record Updates
Last Update Posted (ESTIMATE)
June 4, 2012
Last Update Submitted That Met QC Criteria
May 31, 2012
Last Verified
May 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Musculoskeletal Diseases
- Bone Diseases
- Bone Diseases, Developmental
- Osteochondrodysplasias
- Osteosclerosis
- Osteopetrosis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Dermatologic Agents
- Antifungal Agents
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Calcineurin Inhibitors
- Cyclophosphamide
- Fludarabine
- Methotrexate
- Busulfan
- Thymoglobulin
- Cyclosporine
- Cyclosporins
Other Study ID Numbers
- HORCSCT-0905
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteopetrosis
-
Indiana UniversityHorizon Pharma Ireland, Ltd., Dublin IrelandCompleted
-
Masonic Cancer Center, University of MinnesotaCompleted
-
Rocket Pharmaceuticals Inc.California Institute for Regenerative Medicine (CIRM)TerminatedInfantile Malignant OsteopetrosisUnited States
-
Odense University HospitalCompleted
-
InterMuneCompletedOsteopetrosisUnited States
-
Lundquist Institute for Biomedical Innovation at...University of Minnesota; Horizon Pharma Ireland, Ltd., Dublin IrelandCompleted
-
University of ChicagoTerminated
-
Masonic Cancer Center, University of MinnesotaTerminated
-
St. Jude Children's Research HospitalTerminated
-
FDA Office of Orphan Products DevelopmentMedical University of South CarolinaCompleted
Clinical Trials on Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine (Conditioning regimen)
-
University Hospital, Basel, SwitzerlandUniversity Hospital, Geneva; University Hospital, ZürichCompletedMyeloid Leukemia | Precursor Myeloid Neoplasms | Lymphoid NeoplasmsSwitzerland
-
Institut Paoli-CalmettesAgence de La BiomédecineCompleted
-
Institut Paoli-CalmettesUnknownLeukemia, Myeloid, Acute | Leukemia, Lymphoblastic, AcuteFrance
-
University Hospital, Clermont-FerrandUnknownHematologic Neoplasms | Solid TumorsFrance
-
The Korean Society of Pediatric Hematology OncologyCompletedWiskott-Aldrich SyndromeKorea, Republic of
-
The Korean Society of Pediatric Hematology OncologyUnknownAcute Myeloid LeukemiaKorea, Republic of
-
Emory UniversityNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...CompletedSickle Cell DiseaseUnited States
-
University of Illinois at ChicagoCompletedAcute Myeloid Leukemia | Polycythemia Vera | Multiple Myeloma | Myelofibrosis | Acute Leukemia | Chronic Myelogenous Leukemia | Aplastic Anemia | Myeloproliferative Disorder | Hodgkin's Disease | Malignant Lymphoma | Lymphocytic LeukemiaUnited States
-
The Korean Society of Pediatric Hematology OncologyUnknownAnemia, AplasticKorea, Republic of
-
The Korean Society of Pediatric Hematology OncologyUnknown